Research ExplorerPublicationsAdjuvant therapy-related shortening of survival (ATRESS)

Adjuvant therapy-related shortening of survival (ATRESS)

Standard

Adjuvant therapy-related shortening of survival (ATRESS) : an underrated phenomenon. / Fink, Michael K; Kleeberg, Ulrich R; Bartels, Stefan.

In: ONCOLOGIST, Vol. 20, No. 1, 01.2015, p. 88.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Fink, MK, Kleeberg, UR & Bartels, S 2015, 'Adjuvant therapy-related shortening of survival (ATRESS): an underrated phenomenon', ONCOLOGIST, vol. 20, no. 1, pp. 88. https://doi.org/10.1634/theoncologist.2014-0273

APA

Fink, M. K., Kleeberg, U. R., & Bartels, S. (2015). Adjuvant therapy-related shortening of survival (ATRESS): an underrated phenomenon. ONCOLOGIST, 20(1), 88. https://doi.org/10.1634/theoncologist.2014-0273

Vancouver

Fink MK, Kleeberg UR, Bartels S. Adjuvant therapy-related shortening of survival (ATRESS): an underrated phenomenon. ONCOLOGIST. 2015 Jan;20(1):88. https://doi.org/10.1634/theoncologist.2014-0273

Bibtex

@article{6012f01a113640dcb6cc336e4914859a,
title = "Adjuvant therapy-related shortening of survival (ATRESS): an underrated phenomenon",
abstract = "Shortening of survival after dissemination following adjuvant treatment is not understood well enough and is difficult to search for in public databases because of the lack of specific search terms. We suggest using the acronym ATRESS, for “adjuvant therapy-related shortening of survival,” in future literature concerning this issue.",
keywords = "Breast Neoplasms/drug therapy, Deoxycytidine/analogs & derivatives, Female, Fluorouracil/analogs & derivatives, Humans, Taxoids/therapeutic use",
author = "Fink, {Michael K} and Kleeberg, {Ulrich R} and Stefan Bartels",
year = "2015",
month = jan,
doi = "10.1634/theoncologist.2014-0273",
language = "English",
volume = "20",
pages = "88",
journal = "ONCOLOGIST",
issn = "1083-7159",
publisher = "ALPHAMED PRESS",
number = "1",

}

RIS

TY - JOUR

T1 - Adjuvant therapy-related shortening of survival (ATRESS)

T2 - an underrated phenomenon

AU - Fink, Michael K

AU - Kleeberg, Ulrich R

AU - Bartels, Stefan

PY - 2015/1

Y1 - 2015/1

N2 - Shortening of survival after dissemination following adjuvant treatment is not understood well enough and is difficult to search for in public databases because of the lack of specific search terms. We suggest using the acronym ATRESS, for “adjuvant therapy-related shortening of survival,” in future literature concerning this issue.

AB - Shortening of survival after dissemination following adjuvant treatment is not understood well enough and is difficult to search for in public databases because of the lack of specific search terms. We suggest using the acronym ATRESS, for “adjuvant therapy-related shortening of survival,” in future literature concerning this issue.

KW - Breast Neoplasms/drug therapy

KW - Deoxycytidine/analogs & derivatives

KW - Female

KW - Fluorouracil/analogs & derivatives

KW - Humans

KW - Taxoids/therapeutic use

U2 - 10.1634/theoncologist.2014-0273

DO - 10.1634/theoncologist.2014-0273

M3 - SCORING: Journal article

C2 - 25589500

VL - 20

SP - 88

JO - ONCOLOGIST

JF - ONCOLOGIST

SN - 1083-7159

IS - 1

ER -